Monofer (Ferric Derisomaltose)

Monofer is an intravenous iron preparation used to correct iron deficiency in several clinical settings.

• Iron deficiency anemia: restores hemoglobin levels and replenishes depleted iron stores.
• Chronic kidney disease‑related anemia: provides readily available iron to support erythropoiesis in patients with renal impairment.
• Preoperative anemia: raises hemoglobin concentrations before surgery to reduce peri‑operative transfusion requirements.

• Ferric derisomaltose forms a stable iron‑carbohydrate complex that remains intact in the bloodstream. Upon intravenous administration, the complex releases elemental iron in a controlled manner, allowing incorporation into hemoglobin and other iron‑dependent proteins, thereby correcting iron deficiency and supporting erythropoiesis.

Monofer may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: transient feeling of sickness after infusion.
• Headache: mild to moderate intensity.
• Dizziness: often resolves shortly after administration.
• Injection site reactions: redness, swelling, or pain at the infusion site.
• Transient hypotension: brief drop in blood pressure during infusion.
• Metallic taste: temporary alteration in taste perception.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: prolonged low blood pressure post‑infusion.
• Acute respiratory distress: difficulty breathing or wheezing.
• Iron overload: excessive iron accumulation in organs.
• Elevated liver enzymes: potential liver function abnormalities.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Monofer, consider the following safety measures.

• Renal impairment: monitor iron parameters and renal function closely.
• History of hypersensitivity: avoid if the patient has previously reacted to ferric derisomaltose.
• Cardiovascular disease: observe blood pressure during and after infusion.
• Pregnancy and lactation: use only when the potential benefit justifies the potential risk.
• Concurrent oral iron therapy: may interfere with infusion; consider timing adjustments.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Monofer can interact with other medicines; awareness helps prevent complications.

Major Interactions (Avoid)

• Concurrent intravenous iron agents (e.g., iron dextran): risk of iron overload.
• Simultaneous use with erythropoiesis‑stimulating agents: may exacerbate iron excess.

Moderate Interactions (Monitor Closely)

• Oral phosphate binders: may reduce iron availability if taken close to infusion.
• Antacids: could affect iron release when administered near the infusion time.
• Chelating agents (e.g., deferoxamine): may bind released iron and diminish efficacy.